Physician profile
Lance D Rubel
NPI 1568406460
$1,555.80
in general payments reported to CMS, 2019-2025
18 companies · $256 in 2025
The $256 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $302 · 2020: $53.58 · 2021: $328 · 2022: $275 · 2023: $168 · 2024: $174 · 2025: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $581 · Education: $17.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $580.74 |
| Education | $17.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $389.73 | 2019-2024 | Lokelma, Farxiga |
| Otsuka America Pharmaceutical, INC. | $264.03 | 2019-2025 | Jynarque |
| Recor Medical INC | $138.91 | 2025 | Paradise Ultrasound Renal Denervation System |
| Vifor Pharma, INC. | $134.21 | 2019 | |
| Intuity Medical INC | $118.44 | 2022 | |
| Alexion Pharmaceuticals, INC. | $72.14 | 2023-2025 | Ultomiris |
| Opko Pharmaceuticals, LLC | $64.79 | 2019-2023 | Rayaldee |
| Amgen INC. | $63.27 | 2024-2025 | Krystexxa |
| Ani Pharmaceuticals, INC. | $58.84 | 2022-2023 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $55.56 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $49.08 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $37.90 | 2021-2022 | |
| Akebia Therapeutics INC | $23.48 | 2025 | Vafseo |
| Horizon Therapeutics Plc | $20.92 | 2022 | |
| Lilly USA, LLC | $19.20 | 2024 | Jardiance |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $19.07 | 2019 | |
| Glaxosmithkline, LLC. | $14.60 | 2019 | |
| Fresenius USA Marketing, INC. | $11.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Rubel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.